Asthma Clinical Trial
— PACAPOfficial title:
Towards Participatory Paediatric Asthma Action Plans
Asthma is the most common chronic disease in children. The management of asthma attacks at home is based on asthma action plans that are very heterogeneous and reflect the diversity of recommendations on this subject. The purpose of this study is to observe using smartinhalers how children and their families use their emergency treatment at home in case of asthma symptoms and asthma attacks, to allow building new recommendations based not only on the literature, but also on real-world data.
| Status | Recruiting |
| Enrollment | 150 |
| Est. completion date | June 2023 |
| Est. primary completion date | June 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 3 Years to 11 Years |
| Eligibility | Inclusion Criteria: - Parent of 18 years or more - Parent with a smartphone compatible with a smart inhaler - Parent with child who : - is 3 years to 11 years 11 months old - has physician-diagnosed asthma diagnosis - has a prescription of emergency treatment in case of asthma symptom - Non-opposition of the legal guardian Exclusion Criteria: - Refuse to participate at the study - Difficulty reading and/or understanding French language - Technical problem (malfunction) with the smart inhalers and/or the associated mobile application during the initial test with the parent's smartphone |
| Country | Name | City | State |
|---|---|---|---|
| France | Hôpital Necker-Enfants malades | Paris |
| Lead Sponsor | Collaborator |
|---|---|
| Assistance Publique - Hôpitaux de Paris |
France,
Heidi M, Emily K, Benjamin H, Michael C, Robert K, Mitch B, Chris G, Mando W, Andrew B. Patient reported outcomes for preschool children with recurrent wheeze. NPJ Prim Care Respir Med. 2019 Mar 26;29(1):7. doi: 10.1038/s41533-019-0120-3. — View Citation
Marguet C, Michelet I, Couderc L, Lubrano M. [Management of acute asthma exacerbation in childhood: French recommendations]. Arch Pediatr. 2009 Jun;16(6):505-7. doi: 10.1016/S0929-693X(09)74046-1. French. — View Citation
Pinnock H, Parke HL, Panagioti M, Daines L, Pearce G, Epiphaniou E, Bower P, Sheikh A, Griffiths CJ, Taylor SJ; PRISMS and RECURSIVE groups. Systematic meta-review of supported self-management for asthma: a healthcare perspective. BMC Med. 2017 Mar 17;15(1):64. doi: 10.1186/s12916-017-0823-7. Review. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Mean number of actuations of the emergency treatment in the group "symptom improvement" | Mean number of actuations in asthma attacks asthma attack for which parents think that the emergency treatment has been effective (group "symptom improvement"), for each symptom or symptom association | 18 months | |
| Primary | Mean duration between two actuations of the emergency treatment in the group "symptom improvement" | Mean duration between two actuations in asthma attacks for which parents think that the emergency treatment has been effective (group "symptom improvement"), for each symptom or symptom association | 18 months | |
| Secondary | Mean number of actuations of the emergency treatment between the groups "symptom improvement" and "no improvement" | Mean number of actuations for each symptom or symptom association, between asthma attack for which parents think that the emergency treatment has been effective (group "symptom improvement"), and asthma attacks for which parents think that the emergency treatment has not been effective (group "no improvement") | 18 months | |
| Secondary | Mean duration between two actuations of the emergency treatment between the groups "symptom improvement" and "no improvement" | Mean duration between actuations for each symptom or symptom association, between asthma attack for which parents think that the emergency treatment has been effective (group "symptom improvement"), and asthma attacks for which parents think that the emergency treatment has not been effective (group "no improvement") | 18 months | |
| Secondary | Percentage of asthma attacks treated according to each guideline | Percentage of asthma attacks treated following the GINA guidelines (2 puffs every 10 min), the BTS guidelines (1 puff every 30 seconds with a maximum of 10 puffs), the French guidelines (1 puff/2kg every 20 minutes) | 18 months | |
| Secondary | Percentage of asthma attacks treated according to the asthma action plan of families | For families with an asthma action plan provided by their physician, the percentage of asthma attacks treated by parents according to their asthma action plan will be presented, providing an evaluation of the adherence of families to their asthma action plan. | 18 months | |
| Secondary | Overtreatment by families | For families with an asthma action plan provided by their physician, estimate the percentage of asthma attacks treated with = 150% of the number of puffs prescribed by their physician (for example, the physician prescribed 5 puffs, the child was provided 8 puffs or more). | 18 months | |
| Secondary | Undertreatment by families | For families with an asthma action plan provided by their physician, estimate the percentage of asthma attacks treated with = 50% of the number of puffs prescribed by their physician (for example, the physician prescribed 5 puffs, the child was provided 2 puffs or less | 18 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|